Treventis CEO Christopher Barden attended BioPort, Atlantic Canada’s largest health and life sciences event in Halifax, Nova Scotia. BioPort is the region’s annual forum for education, information, and inspiration of the Atlantic Canadian life sciences ecosystem. At the event, Dr. Barden networked with the local community about Treventis and particularly as regards its Halifax-based butyrylcholinesterase […]
Treventis CSO Mark Reed attended the Texas Life Science Forum on November 7th in Houston, Texas, an event that brought together life science industry members, including companies, academia, and investors. During the forum, Treventis CSO Mark Reed gave an invited presentation on proteinopathies and the Treventis approach to dealing with them.
CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are working in the areas of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and muscular dystrophy, as well as other rare diseases with neuromuscular symptoms. This year’s summit surveyed biomarkers, clinically meaningful endpoints, and regulatory challenges […]
Treventis was represented at the 50th Society for Neuroscience Conference in Chicago, Illinois, one of the world’s largest conferences dedicated to brain research. Among the topics addressed in Chicago: mouse models of Alzheimer’s disease and other neurodegenerative disorders; seeding (Tau & Aβ) models; and new developments in the therapeutic landscape for AD. Treventis has an […]
Treventis CEO Christopher Barden was honored to be an invited speaker at the XV International Pharma Licensing Symposium, running from Sep 18-20, 2019, in Paris, France. This year’s topic was “Disruption or Evolution? Contemporary Trends in Pharma Business Development.” Topics at this year’s IPLS included artificial intelligence, medical cannabis, diseases of aging, and evolution of […]
Treventis was represented at the 4th Zebrafish for Personalized & Precision Medicine Conference, running from Sep 18-20, 2019, in Toronto, Ontario. In attendance was VP Research Marcia Taylor, who chaired one of the symposia. The main objective of the conference is to apply research knowledge in zebrafish to applications that would allow for so-called ‘humanized’ […]
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 14-18, 2019, in Los Angeles, California. In attendance were CEO Christopher Barden, VP Research Marcia Taylor, and Chief Medical Officer Dr. Donald Weaver. Dr. Weaver presented a poster entitled “Efficient Computational Algorithms for Predicting Brain Permeability and Effect of Transporters.” In this […]
Treventis attended the BIO International Convention that took place on June 3-6 in Philadelphia, Pennsylvania, with more than 16,000 attendees passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients. This year, Treventis was a “Buzz of BIO” competition finalist and was invited to speak […]
Treventis scientists attended the 14th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders held on March 26-31 in Lisbon, Portugal. This conference focuses on the most current findings in understanding pathogenesis mechanisms, as well as new clinical strategies and treatments of AD and PD. During the conference visit, it became apparent that […]
FEB 22, 2019 – Treventis is pleased to announce that internationally recognized ALS researcher Dr. Janice Robertson has joined its Scientific Advisory Board. Dr. Robertson, a Canada Research Chair in Amyotrophic Lateral Sclerosis and a Ontario Premier Research Excellence awardee, is Professor at the Tanz Centre for Research in Neurodegenerative Diseases and of the Department […]